Brox.AI’s Hamish Brocklebank on why it retired “digital twin” for “digital clone” — and why the distinction matters for pharma research accuracy.
Feature|Articles|September 15, 2026
Pharma Now Has Two Audiences — People and Machines: Q&A with Stewart Gandolf
Author(s)Mike Hollan, Stewart Gandolf
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Advertisement
Advertisement
AI became the most common way people search the internet. Not surprisingly, the new technology impacted that way that people search, including patients. Now, instead of keyword searching, many experts are saying that people search by question.
Related to this article
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Pfizer’s talazoparib-enzalutamide combination moves to earlier line in prostate cancer, with eligibility tied to genetic testing and immature survival data.
Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement